Industry Seeks More Clarity on Proposed Federal Stem Cell Research Rules
The nation's leading industry group for regenerative medicine today called for a clearer federal pathway to help bring stem cell products to the marketplace.
The Alliance for Regenerative Medicine (ARM), which has 240 business, academic and patient advocacy members, testified today at a Food and Drug Administration hearing into proposals for more regula…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.